Equities

Arcellx Inc

ACLX:NSQ

Arcellx Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)85.43
  • Today's Change4.88 / 6.06%
  • Shares traded752.68k
  • 1 Year change+136.06%
  • Beta--
Data delayed at least 15 minutes, as of Sep 19 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of USD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments702255105
Total Receivables, Net------
Total Inventory------
Prepaid expenses12128.19
Other current assets, total1.90----
Total current assets716267113
Property, plant & equipment, net704010
Goodwill, net------
Intangibles, net------
Long term investments27----
Note receivable - long term------
Other long term assets9.364.562.28
Total assets825314129
LIABILITIES
Accounts payable2.629.051.33
Accrued expenses261513
Notes payable/short-term debt000
Current portion long-term debt/capital leases3933--
Other current liabilities, total5100.33
Total current liabilities1185715
Total long term debt0210
Total debt39540
Deferred income tax------
Minority interest------
Other liabilities, total222312.07
Total liabilities34010917
SHAREHOLDERS EQUITY
Common stock0.050.040.00
Additional paid-in capital8745248.62
Retained earnings (accumulated deficit)(389)(319)(130)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total0.55(0.22)(0.02)
Total equity485205112
Total liabilities & shareholders' equity825314129
Total common shares outstanding524435
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.